Interactions between the European Medicines Agency and US Food and Drug Administration September 2009-September 2010

Author (Corporate) ,
Publisher
Publication Date 23/06/2011
Content Type

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), in June 2011, set up a new 'cluster' on biosimilar medicines.

Clusters are topic areas of mutual interest for the two agencies, which they have identified as benefiting from the regular exchange of information and collaborative meetings. Biosimilar medicines is the latest addition to the existing list of topics, which already includes medicines to treat cancer, orphan medicines, medicines for children and blood-based products.
Source Link Link to Main Source http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/06/WC500107900.pdf
Related Links
EMA: News, 23.6.11: European Medicines Agency and US Food and Drug Administration set up biosimilar 'cluster' and publish first report on interactions http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001282.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
Subject Categories
Countries / Regions ,